Literature DB >> 12859388

The crescentic advancement flap revisited.

Simon S Yoo1, Stanley J Miller.   

Abstract

BACKGROUND: When closing surgical defects, optimal aesthetic results are obtained when cosmetic units are preserved and, whenever possible, when scars are placed in naturally occurring creases and folds. This is particularly challenging in the perialar region, where surgical defects can encompass more than one cosmetic subunit.
OBJECTIVE: To examine the reconstructive options and to demonstrate that the crescentic advancement flap for closures of defects in the perialar area is a superior alternative.
METHODS: This is a review of surgical approaches, a historical examination of perialar repairs, and an illustrative case.
RESULTS: A patient with a perialar defect was reconstructed using the crescentic advancement flap with excellent postoperative results.
CONCLUSION: When compared with the other options, whenever feasible, the crescentic advancement flap, which has evolved over the years, remains a superior option for defects in the perialar location.

Entities:  

Mesh:

Year:  2003        PMID: 12859388     DOI: 10.1046/j.1524-4725.2003.29232.x

Source DB:  PubMed          Journal:  Dermatol Surg        ISSN: 1076-0512            Impact factor:   3.398


  3 in total

1.  Outcome of Flap Surgeries in Dermatosurgical Unit at a Tertiary Care Centre in India with a Review of Literature.

Authors:  Gorur Kalappa Divya; Kanathur Shilpa; Sacchidanand Sarvajnamurthy; Eswari Loganathan; Biju Vasudevan; G B Chitrika; C Madhura; D V Lakshmi
Journal:  J Cutan Aesthet Surg       Date:  2016 Oct-Dec

2.  Nasal Ala Reconstruction: Surgical Conundrum.

Authors:  Ana Ortins-Pina; Ana Isabel Teixeira; Maria Sanches; Ana Isabel Gouveia; Paulo Leal Filipe; João Maia Silva
Journal:  J Cutan Aesthet Surg       Date:  2017 Jan-Mar

3.  Versatility of advancement flaps for nasal reconstruction following Mohs` micrographic surgery.

Authors:  Felipe Bochnia Cerci
Journal:  An Bras Dermatol       Date:  2018 Sep-Oct       Impact factor: 1.896

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.